Apr 7, 2022 | Press release
Södertälje, Sweden, 7th April 2022 – Anocca, a biotechnology company using its precision biology platforms to engineer a broad portfolio of innovative T cell therapeutics, today announced the appointment of Dr. Michael Kalos to its Scientific Advisory Board (SAB). Dr....
Feb 22, 2022 | Press release
Södertälje, Sweden, February 22, 2022 – Anocca AB, a pioneer in T cell immunotherapy, today announces it has made a number of appointments to expand its senior leadership team and strengthen its business development and R&D capabilities. This includes the...
Sep 8, 2021 | Press release
Södertälje, Sweden, 8 September 2021 – Anocca AB, a leader in unlocking the potential of T-cell immunotherapy to deliver transformative therapeutics, today announced the appointment of Jacob Michlewicz as Chief Financial Officer, effective immediately, and based at...
Sep 8, 2021 | Press release
Södertälje, 8 september 2021 – Anocca AB, ett världsledande svenskt bioteknikbolag för utveckling av T-cellsbehandlingar mot cancer, autoimmuna sjukdomar och virusinfektioner, tillkännagav idag utnämningen av Jacob Michlewicz till CFO, med omedelbar verkan. Han är...
Jul 22, 2021 | Press release
Södertälje, Sweden, 22 July 2021 – Anocca AB, a leader in unlocking the potential of T-cell immunotherapy to deliver transformative therapeutics for cancer, today announced the closing of a USD 47 million (SEK 400 million) Series B financing to further advance the...
Jul 22, 2021 | Press release
Södertälje, 22 juli 2021 – Anocca AB, ett världsledande svenskt bioteknikbolag för utveckling av T-cellsbehandlingar mot cancer, autoimmuna sjukdomar och virusinfektioner, meddelade idag att bolaget har stängt en serie B-finanseringsrunda på 400 miljoner kronor (47...
